This page is about one specific scenario: the dermatoscope was used and the melanoma was still missed. That is different from our broader guide to melanoma misdiagnosis and Breslow staging, which covers whether a mole should have been examined or referred in the first place. It is also different from a misread scan, biopsy or histopathology result, and from a laboratory misreading an excised tissue sample.

Here the failure happened at the optical or digital examination, before any tissue diagnosis. We focus on when that founds a claim under Irish law.

How a melanoma can be missed when dermoscopy is used in Ireland

Dermoscopy, also called dermatoscopy, is the examination of a skin lesion under magnification with polarised light. It lets a trained clinician see colours and structures below the surface that the naked eye cannot. Used well, it improves melanoma detection by roughly 20 to 30 per cent over naked-eye inspection.^[4] Many Irish dermatologists, and a growing number of GPs with extended dermatology roles, use it routinely.

The problem this page addresses is narrower. A dermatoscope is only as good as the person reading it, and reading it well depends on training and experience. The standard of pigmented-lesion recognition among Irish GPs varies widely, from those with formal dermoscopy qualifications to those with little training.^[5] A clinician can hold the scope to a lesion, record that it looks benign, and reassure the patient, while the melanoma was there to be found.

Dermoscopy is also operator-dependent in a way that matters for proof. Two competent clinicians can look at the same lesion and reach different judgments, because reading subsurface structures involves interpretation, not a fixed measurement. That is why an independent expert who re-reads the stored image or the clinic record is central to these claims. The recorded image fixes what was actually visible, so the question becomes what a careful clinician should have made of it.

The lesion that gets missed is usually one that changed. A 2026 study in the Irish Medical Journal of pigmented-lesion referrals found that a changing mole was the single most common reason for referral, accounting for 151 of 362 patients, or 41.7 per cent.^[18] A changing mole examined under dermoscopy and then cleared, with no plan to look again, is the exact pattern these cases turn on.

Patients describe this scenario often. A mole is checked at a GP visit or a private clinic, the patient is told it looks fine, and a thicker melanoma is diagnosed six to eighteen months later. The trust placed in the examination is exactly what makes a later diagnosis so distressing.

A personal injury claim does not turn on the shock of that experience. It turns on whether the examination fell below the standard a competent practitioner would have met.

Why dermoscopy can return a false negative

A false-negative dermoscopy means the scope was used but the lesion was wrongly judged harmless. Two things drive it: the melanoma itself, and the safeguard the clinician should have applied when the picture was unclear.

Some melanomas genuinely look unremarkable at a single visit. According to a 2021 study in the Journal of the American Academy of Dermatology, around 60 per cent of the melanomas later diagnosed on digital dermoscopic monitoring were "featureless" at the point of diagnosis, recognisable only by comparing the lesion side by side with an earlier baseline image.^[6] Amelanotic melanoma, which lacks dark pigment and looks pink, red, or skin-coloured, is frequently mistaken for eczema, dermatitis, or a harmless blemish. Nodular melanoma grows downward rather than spreading sideways, so it can look small and symmetrical while being deeply invasive.

This is where the recognised safeguard matters. When a melanocytic lesion is suspicious but does not show clear melanoma features, the accepted approach is short-term sequential digital dermoscopic monitoring: re-imaging the lesion after about three to four and a half months and comparing the images for change, or simply removing the lesion if doubt remains.^[6] A documented case describes a melanoma repeatedly missed at a specialist pigmented lesion clinic despite dermoscopy, because the only clue was an unusual vascular pattern that a structured approach would have flagged.^[7]

There is a recognised method experts use to read these lesions, known as the two-step dermoscopy algorithm.^[19] The first step decides whether a lesion is a mole at all. The second step looks for the specific patterns that point to melanoma.

A lesion that shows no clear diagnostic structures falls into a default category. The rule for that category is the safeguard itself: such a lesion should be biopsied or placed on short-term monitoring, precisely so a featureless melanoma is not cleared by mistake.^[19]

This method is not a statutory standard, and a court does not apply it as a checklist. It matters because it shows what a careful reading involves. In the dermoscopy cases we review, an expert often measures what the clinician recorded against this kind of structured approach, and the gap is where a breach can be shown.

The breach, in legal terms, is usually not that dermoscopy was unavailable. It is that an equivocal or changing lesion was cleared with no monitoring, no biopsy, and no referral, when a careful clinician would have used one of those safeguards. The melanoma being "featureless" at one visit is the reason the safeguard exists, not a defence to skipping it.

The dermoscopic features that should raise suspicion

Certain structures seen under dermoscopy are recognised warning signs. They do not diagnose melanoma on their own, and a benign mole can show some of them. The point for a claim is different: where these features are clearly visible and a competent clinician records the lesion as benign without biopsy, referral, or monitoring, and the lesion later proves to be a thicker melanoma, that supports an argument that the examination fell below the expected standard.

An expert dermatologist instructed in a claim reviews the recorded images or notes against what a competent practitioner should have seen. Where a clearly visible high-risk feature was present and not acted on, that comparison becomes the foundation of the breach argument, tied to how far the melanoma then progressed.

Teledermatology and mole mapping: newer failure points

Two technologies are changing how pigmented lesions are assessed in Ireland, and each creates its own way for a melanoma to be missed.

Teledermatology. To ease pressure on dermatology waiting lists, which held over 60,000 patients in June 2025 with some people waiting up to three years for a routine appointment, the HSE has moved toward a "store-and-forward" model.^[8] A GP or a trained nurse photographs the lesion, including dermoscopic images, and sends them with the referral. A consultant dermatologist then reviews the images remotely and decides whether the patient needs a face-to-face appointment, a biopsy, or can be discharged.

In April 2026 the Health Information and Quality Authority published a health technology assessment on this pathway.^[9] It concluded that store-and-forward teledermatology is safe and effective when used as part of a complete clinical pathway. That qualifier is where liability can arise.

If the captured image is out of focus, poorly lit, or misses the edge of the lesion, the reviewing consultant is judging an inadequate picture. If the consultant receives an equivocal image and discharges the patient instead of upgrading them to a face-to-face assessment, a melanoma can be missed. There is also no touch in a remote review, so the firmness that helps identify a dangerous nodular melanoma cannot be felt. A missed melanoma here can involve more than one party, from the person who took the image to the consultant who read it.

Mole mapping. Sequential digital dermoscopy, marketed as mole mapping, photographs a person's moles to a baseline and compares new images at later visits to detect change. In law it is a medical record, not a treatment in itself. That makes it powerful evidence.

Where a clinic holds time-stamped images that show a lesion changing across visits, and the clinician failed to act on that change before an advanced melanoma was diagnosed, the photographic timeline gives clear, dated proof of what could have been seen and when. These records are disclosable, and obtaining them early is often decisive.

Who you claim against depends on where the check happened. Many mole-mapping and teledermatology services in Ireland are private. A missed melanoma at a private skin clinic is a claim against that clinic and its insurer, not against the State. A miss in a public HSE pathway is handled through the State indemnity system.

If your care crossed both, for example a private mole-map followed by a public referral, more than one claim may be needed. That is another reason to identify every clinician involved early.

The standard of care for dermoscopy under Irish law

Irish medical negligence is judged by the Dunne principles from Dunne v National Maternity Hospital [1989] IR 91, reaffirmed by the Supreme Court in Morrissey v HSE [2020] IESC 6.^[1] A practitioner is negligent only if they did something no practitioner of equal status and skill, acting with ordinary care, would have done. This is not the English Bolam test, and UK guidance on these claims can mislead on both the standard and the time limit.

Morrissey drew a useful distinction between the standard of approach, meaning what a competent clinician actually does, and the legal standard of care.^[1] Applied here, if using dermoscopy or short-term monitoring is the accepted approach for a high-risk lesion, failing to use it can fall below the legal standard. A further principle in Dunne is that a clinician cannot rely on a usual practice if that practice has an inherent defect that should be obvious to anyone considering it.

One feature of these cases is specific to dermoscopy. Irish GPs receive no mandatory comprehensive dermoscopy training in standard GP training, and competent use depends on postgraduate learning through bodies such as the Irish College of General Practitioners and the Primary Care Dermatology Society of Ireland.^[5]

A GP who advertises advanced dermoscopy skills, holds a diploma, and uses a dermatoscope, then misreads the structures, may be measured against a higher standard than a GP who relies on the naked eye and refers the patient on. The duty in primary care is usually not to diagnose the melanoma, but to recognise the suspicion and trigger the correct referral.

The Irish referral route is the NCCP National Pigmented Lesion GP Referral pathway, sent electronically through Healthlink to a Pigmented Lesion Clinic, with the GP marking the referral as urgent, soon, or routine according to the level of suspicion.^[10] The guidelines also direct that suspicious pigmented lesions be referred intact and not shave-excised or punch-biopsied in primary care, because an inadequate sample can return a false-negative result while the melanoma keeps growing.^[10] Clinical guidelines guide practice without replacing the Dunne standard, a point confirmed in Perez v Coombe Women and Infants University Hospital [2025] IEHC 396.^[11]

Proving the dermoscopy delay caused harm

Proving a breach is only the first step. Under Irish law you must also prove, on the balance of probabilities, that the delay caused real harm. In melanoma cases the objective measure is Breslow thickness, which records how deep the tumour has grown in millimetres and drives staging, treatment, and prognosis.^[2]

The legal question is whether the dermoscopy delay let the tumour cross a staging threshold. A melanoma caught thin may need only a wide local excision. The same melanoma allowed to grow deeper can require sentinel lymph node biopsy, wider surgery and reconstruction, and systemic immunotherapy, with a poorer outlook.

An expert reconstructs how thick the lesion probably was at the missed examination and how thick it was at diagnosis. That difference is the injury. For a fuller explanation of how a change in stage becomes legal damage, see our guide to reduced life expectancy in cancer claims.

Where survival was already uncertain, the loss of chance doctrine can still apply, though Irish law is not settled here. The Supreme Court recognised recovery for a lost treatment opportunity in Philp v Ryan [2004] IESC 105, where Fennelly J increased the award from €45,000 to €100,000 for an eight-month delay in diagnosing prostate cancer.^[12] A year later, in Quinn v Mid-Western Health Board [2005] IESC 19, the same court applied the strict but-for test.^[13] The tension between them is unresolved, so this needs specialist advice.

Causation in cancer delay can be hard to prove for a reason practitioners describe as the doubling-time problem. A slow-growing tumour lets the defence argue the delay changed little, while a fast-growing one lets them argue the cancer was not yet detectable at the earlier date. In Crumlish v HSE [2024] IECA 244, a breast cancer claim failed where the doubling-time evidence did not support the claimant.^[14]

In the dermoscopy cases we review, the recorded images are often the strongest answer to that defence, because they pin down what was visible and when. We use them to anchor the expert timeline rather than rely on retrospective estimates alone.

What a claim may include

Compensation in an Irish clinical negligence claim has two parts. General damages cover pain, suffering, and loss of amenity, assessed under the Personal Injuries Guidelines (2021), where the ceiling for the most catastrophic injuries is about €550,000.^[15] A proposed 16.7 per cent increase was approved by the Judicial Council but the Government decided in July 2025 not to bring it to the Oireachtas, so the 2021 figures still apply.^[16] Special damages are uncapped and cover financial losses such as the cost of private immunotherapy, lost earnings, and care.

A melanoma claim often combines several elements. Wider or deeper surgery and skin grafts cause scarring and disfigurement, which has its own valuation bands. A delayed cancer diagnosis commonly causes a separately compensable psychiatric injury, including anxiety and a lasting fear of recurrence sustained through years of surveillance. Where multiple injuries exist, the court identifies the dominant injury and adds a proportionate uplift for the others.

A common worry is whether your own delay in going back to the doctor ends the claim. Under the Civil Liability Act 1961, a later delay on your part may reduce damages for contributory negligence, often in the region of 10 to 25 per cent, but it does not remove the clinician's primary liability. You are not medically trained and cannot be expected to diagnose an evolving melanoma. For how a worth figure is built across these heads, see our guide to what a cancer misdiagnosis claim may include.

Time limits and date of knowledge

The limitation period for a melanoma negligence claim in Ireland is two years less one day, and it runs from your date of knowledge, not from the date of the missed examination.^[3] The date of knowledge is when you knew, or ought reasonably to have known, that you suffered a significant injury connected to negligence. In a dermoscopy case that is often the day a later diagnosis revealed that an earlier "clear" check had missed the melanoma.

The Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023, commenced in September 2024, requires mandatory open disclosure of a closed list of specified serious "notifiable incidents" set out in Schedule 1, which are primarily death-related events rather than missed diagnoses generally. A delayed cancer diagnosis will not, in itself, ordinarily be a notifiable incident under that Schedule. Separately, where a hospital later reviews your earlier images and identifies a missed feature, any apology or disclosure made cannot be used against the hospital as an admission of liability, but the underlying records can still be obtained.^[17]

Because the deadline is strict, and securing imaging and pathology early can decide a case, it is worth taking advice without waiting for treatment to finish. Missing the two-year deadline removes your right to pursue compensation for the injury, however strong the claim.

How we can help

If your melanoma was missed despite a dermoscopy check, mole mapping, or a teledermatology review, the first step is to read the record of what was examined. As personal injury solicitors in Dublin, we request your full GP and clinic notes, the original dermoscopic and mole-mapping images, and your pathology and staging, then instruct an independent consultant dermatologist and oncologist to assess what should have been seen and what the delay cost you. We act for clients across Ireland and handle the process so you can focus on your treatment.

In a dermoscopy case, a few specific records usually do most of the work. They are the digital artefacts unique to this kind of claim, and obtaining them early protects their quality.

• The original dermoscopic images, not just the note that a scope was used.
• Any mole-mapping baseline and the later comparison images, with their dates.
• For a teledermatology review, the image that was sent and the consultant's triage decision.
• The referral record, showing whether the urgent NCCP pathway or a routine route was used.
• The histopathology report and the Breslow thickness at diagnosis.

Medical negligence claims do not go through the Injuries Resolution Board. They fall outside the categories of action to which the PIAB Act 2003 applies under section 3, and so proceed directly through the High Court Clinical Negligence List, with no board assessment step to wait for. You can arrange a confidential consultation to understand your options.

Common questions

Related guides: melanoma misdiagnosis and Breslow staging • misread scan, biopsy or histopathology • failure to monitor a patient • pathology and laboratory errors • cancer misdiagnosis claims